Evidence map›Paper›PMID 34853104›Full record

ArticleBMJ open2021

Disparities by sex in P2Y

Ryan P Hickson, Anna M Kucharska-Newton, Jo E Rodgers, Betsy L Sleath, Gang Fang

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Optimal P2YAmerican heart journal plus : cardiology research and practice · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ryan P HicksonDivision of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA ryan.hickson@unc.edu.ORCID 0000-0002-3448-589X
Anna M Kucharska-NewtonDepartment of Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0001-9864-467X
Jo E RodgersDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Betsy L SleathDivision of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Gang FangDivision of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
University of North Carolina at Chapel Hill · US

Funding

North Carolina Translational & Clinical Sciences Institute (NC TraCS)UL1TR001111 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, CAREY, TIMOTHY S · 2013 to 2017
$43.9M
Cardiovascular Epidemiology Training GrantT32HL007055 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Wayne D. Rosamond · 1986 to 2026
$10.0M
NCATS NIH HHS UL1 TR001111NHLBI NIH HHS T32 HL007055
6 · The paper itself

Abstract

objectivesTo determine if comparable older women and men received different durations of P2Y

designRetrospective cohort.

setting20% sample of 2007-2015 US Medicare fee-for-service administrative claims data.

participants≥66-year-old P2Y PRIMARY AND SECONDARY OUTCOME MEASURES: Primary outcome: P2Y SECONDARY OUTCOMES: clinical events while on P2Y

results10 486 women matched to 10 486 men with comparable predicted risks of all 4 study outcomes. No difference in treatment discontinuation was observed at 12 months (women 31.2% risk; men 30.9% risk; RR 1.01; 95% CI 0.97 to 1.05), but women were more likely than men to discontinue therapy at 24 months (54.4% and 52.9% risk, respectively; RR 1.03; 95% CI 1.00 to 1.05). Among patients who did not discontinue P2Y

conclusionsRisks for death/hospice and ischaemic events were lower among women still taking a P2Y

Indexed as

Duration of TherapyMyocardial InfarctionAgedCohort StudiesFemaleHumansMaleMedicarePlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsRetrospective StudiesUnited StatesPlatelet Aggregation InhibitorsPurinergic P2Y Receptor Antagonistsclinical pharmacologyepidemiologygeriatric medicinemyocardial infarctionstatistics & research methods

Identifiers

PMID34853104
PMCPMC8638457
OpenAlexW3217102253

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.